UNSPSC 51262410: Labetalol hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H24N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1GEV3BAW9J, chemically known as benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)- but more generally known as labetalol hydrochloride, which bears US NIH Compound Identifier 3869. European Medicines Agency schedules Labetalol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02844MIG.

UNSPSC 51262410 Labetalol hydrochloride is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities tagged under it do not align with procurement of labetalol itself. Instead, the tagged solicitations reflect purchases of naloxone (an opioid antagonist) and direct-to-manufacturer pharmacy benefit administration services — neither of which are labetalol products. The code shows minimal relevant recent activity for the nominal commodity; state and local buyers are acquiring these pharmaceuticals and pharmacy services under different procurement vehicles and may be applying the labetalol code incorrectly or using it as a placeholder within broader pharmaceutical purchasing frameworks.

The two recent opportunities reflect distinct procurement models. Seminole County, Florida posted an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, to procure 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026, to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory procurement mechanism seeking information on direct contracting between state agencies and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. Geographic activity is limited to Florida and Texas in the recent record, and issuing bodies include a county health department and a state health commission. The absence of substantive labetalol-specific opportunities suggests that firms pursuing this code should verify whether state and local buyers are actively soliciting labetalol products under this code or whether the tagging reflects data-quality issues in the underlying procurement systems.